- If you are wondering whether Veeva Systems at around US$159.54 is a bargain or a value trap, the key questions are what the stock is worth today and how that compares with its current price.
- The share price is down 7.6% over the past week and down 27.3% year to date, with a 43.5% decline over the past year and a 48.0% decline over five years. This naturally raises questions about how the market is reassessing the company and its risks.
- Recent headlines have focused on Veeva Systems as part of broader discussions about health care software stocks and changing expectations for subscription based business models. This context helps explain why the stock's longer term returns and recent short term moves have become a focal point for valuation minded investors.
- Right now, Veeva Systems has a valuation score of 3 out of 6, which suggests the stock screens as undervalued on about half of the checks used. The next step is to compare traditional valuation approaches with a more complete way of thinking about what the company could be worth.
Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a stock could be worth by projecting its future cash flows and discounting them back to today, using a required return to reflect risk and the time value of money.
For Veeva Systems, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s latest twelve month free cash flow is about $1.64b. Analyst and extrapolated projections suggest free cash flow reaching around $2.34b by the 2031 financial year, with intermediate annual projections between those two points prepared by multiple analyst sources and extended by Simply Wall St beyond the usual five year analyst window.
Aggregating and discounting these projected cash flows produces an estimated intrinsic value of about $282.82 per share. Compared with the recent share price of roughly $159.54, the DCF output suggests the stock trades at a 43.6% discount to this intrinsic estimate, which appears meaningfully undervalued on this model alone.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 43.6%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.
Approach 2: Veeva Systems Price vs Earnings
For profitable companies, the P/E ratio is a useful way to link what you pay for the stock to the earnings the business is currently generating. In general, higher expected growth and lower perceived risk often justify a higher “normal” or “fair” P/E, while slower growth or greater risk point to a lower one.
Veeva Systems currently trades on a P/E of 27.52x. That sits above the Healthcare Services industry average of 26.15x and below the peer average of 32.30x. On their own, those comparisons only tell you how the stock lines up against broad groups, without adjusting for Veeva Systems specific growth profile, margins, size and risks.
Simply Wall St’s Fair Ratio is designed to fill that gap. It is a proprietary estimate of what Veeva Systems P/E might reasonably be, given factors such as earnings growth, industry, profit margin, market cap and risk characteristics. For Veeva Systems, the Fair Ratio is 27.38x, which is very close to the current 27.52x P/E, suggesting the market price is broadly in line with this model based assessment.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Veeva Systems Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Veeva Systems future revenue, earnings and margins to a forecast and a Fair Value that you can compare with the current price. All of this is available within an accessible tool on the Community page that updates automatically when fresh news or earnings arrive. One investor might lean toward a cautious Narrative that lines up with a Fair Value near US$232.80, while another might back a more optimistic Narrative closer to US$380.00. Seeing those side by side helps you decide whether the current share price looks high, low or about right for the story you believe.
Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com